LeverVenture is an operator-led, mid-market growth equity firm in life sciences and healthcare, the bridge between venture capital and private equity. These pieces cover that passage: deal structures, market conditions, finance and the operating work that carries a company from proof to scale.
Field notes, diligence method, operating and capitalWritten by the partner or operator who did the work
§ 01 / 02
The archive
Filed under Growth Equity, newest first.
The most recent piece leads and every other piece in this category follows it, each with the line that says what it covers. The other categories are one link away.
Most recent
Growth Equity17 Sep 2026 · 15 min read
Growth Equity in Life Sciences: 2026 Market Study
Growth equity is absorbing a growing share of life sciences and healthcare capital. This market study breaks down the data, the five sectors in play, and where the financing gap actually sits.
Everything else filed under Growth Equity, newest first.
Growth Equity16 Sep 2026 · 11 min
Operational Due Diligence: The GP Checklist Nobody Publishes
Operational due diligence tests whether a manager's documents describe what the firm actually does. The checklist and reference-call script a general partner should expect to answer.
Private Equity Meets the Mid-Market: Borrowing PE's Discipline Without the Buyout
Private equity and venture are converging in the mid-market. What growth companies should borrow from PE — operational value creation, cash discipline, governance — and what they should refuse: control and leverage.
The Operating Record: What It Supports and What It Does Not
An operating record shows what partners did inside companies. Read by evidence class, it supports claims about capability and conduct, not returns or causation.
Family Office Guide to Emerging Growth Equity Managers
A practical framework for family offices evaluating first-time and early-fund growth equity managers: what to check, what to ignore, and the red flags that matter most.
The Term Sheet Guide for Life Sciences and Healthcare Founders
Term sheets carry more weight than the valuation headline. This guide walks life sciences and healthcare founders through the economic terms, control terms, and sector-specific issues to watch.
The State of Venture Capital: How the Power Law Broke the Middle — and What Comes Next
Venture capital is a power-law business, and the end of cheap money exposed a missing rung in the ladder — the Series B/C graduation problem. Why DPI is back, and where the orphaned middle finds capital.
What a First-Time Fund's Back Office Actually Looks Like
A first-time fund rents most of its back office. The general partner keeps oversight, valuation, the compliance calendar and cash authority, and failures start at the handoffs.
Operator-Led vs. Financial-Sponsor Growth Equity: What an Operating Partner Changes for LPs
Two models of growth capital get lumped together as "private equity." This piece separates operator-led from financial-sponsor growth equity and what the difference means for LPs.
The Finance of Scaling: A Growth-Stage Operator's Guide to the Metrics That Move Enterprise Value
The financial rules change between the seed round and the buyout. A growth equity guide to unit economics, the Rule of 40, capital structure, cash strategy, and the metrics that actually move enterprise value.
The J-Curve Is Different in Life Sciences, and Allocators Should Price It
In life sciences, regulatory clocks set the J-curve. Drug approval takes 10.5 years on average from Phase I, so the trough runs longer and reported value moves in steps.
DPI Is the Only Number an Allocator Should Trust Right Now
Median DPI for 2018 to 2020 private equity vintages runs from 0.56x down to 0.16x while TVPI and IRR stay high. Most reported value is still a mark; DPI is the figure settled in cash.
Dual-Use Deep Tech: The Defense-Adjacent Growth-Equity Playbook for Founders
Defense-adjacent deep tech is reshaping how founders in life sciences, clean tech, and AI should structure their commercialization and funding strategy. Here's the operator-level view.
Carried Interest: European and American Waterfalls, Side by Side
On one hypothetical $100 million fund, a deal-by-deal waterfall pays $15 million of carry by year three and a whole-of-fund waterfall pays $10 million. A clawback closes the gap.
Emerging Growth Equity Managers: The Founder's Complete Evaluation Guide for 2026
How founders in life sciences, deep tech, and cleantech should evaluate emerging growth equity managers — track record, fund economics, GP skin-in-the-game, and red flags.
Best Growth Equity Firms for Life Sciences in 2026: A Founder's Field Guide
Who actually funds life sciences growth rounds, what each pool of capital is built for, where the mid-market gap sits, and the questions that vet a partner.
The Operating Partner's First Hundred Days, With Owners and Dates
A minority investor's operating partner runs no workstreams. The first hundred days rest on written rights, a compliance baseline and a plan with owner roles and dates.
Key Person, GP Commitment and Source of Funds in a Two-Partner Firm
In a two-partner firm, the key person provision, the GP commitment and its source of funds work as one alignment mechanism. ILPA's Model LPA and Principles 3.0 set the market form.
A continuation fund puts the sponsor on both sides of a sale. With the SEC fairness-opinion rule vacated, the fiduciary duty, the LPA and ILPA's 2023 guidance govern the choice.
An SPV, a pooled fund and a direct co-investment can hold the same shares, but each answers the Investment Company Act, Regulation D and adviser questions differently.
A minority growth investor works through four levers: a board seat, information rights, protective provisions and operating engagement. Each has a documented use and a documented limit.
VC Market Reset: Implications for Growth Equity Investors
A venture repricing shows up in preference stacks and flat rounds before it shows up in a press release. Here is how a reset moves through a cap table.
Secondary Markets in Growth Equity: 2025 Liquidity Revolution
Secondary markets hit all-time highs in the first half of 2025, with transaction volume above $103 billion. Growth equity investors gain new routes to liquidity.
SaaS Business Models: Evolution Beyond the Rule of 40
The Rule of 40 flattens very different SaaS businesses into one score. Retention composition, cohort payback, margin trend and burn multiple tell them apart.
The first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.
01
Executive summary
Free, no form. The findings, the method and every chart that carries one — complete, not
a teaser, and the same text that opens the full report.
02
The full report
Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no
list you did not ask to be on.